Nanoscale Proteomic Analysis of Oncoproteins in Hematopoietic Cancers
Final rept. 15 Apr 2009-14 Apr 2012
STANFORD RESEARCH INST MENLO PARK CA
Pagination or Media Count:
The goal of our grant was to develop two novel nanoscale proteomic technologies, NIA and AutoChIP, for the analysis of clinical specimens in response to targeted therapeutics. Over the three-year funding period, we have made excellent progress achieving these goals. Indeed, we have exceeded our objectives as follows 1. We have identified the molecular mechanism of a novel PLK1 inhibitor, ON01910.Na, for the treatment of MDS. 2. We have identified biomarkers that appear to predict the clinical activity of this drug for MDS. 3. We have built an independent AutoChIP instrument in the Felsher laboratory, which enables us to unlimited access to this technology. 4. We have optimized conditions for AutoChIP-seq that will enable us to understand the molecular mechanism of targeted therapeutics by profiling global changes of gene activation and inactivation. Finally, during the three years of funding period, we have generated five published papers, two manuscripts in preparation, and we have also presented the DoD supported work in over 50 oral and poster presentations.
- Medicine and Medical Research